Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Evaluation of protein biomarkers of prostate cancer aggressiveness

Authors: Anthony E Rizzardi, Nikolaus K Rosener, Joseph S Koopmeiners, Rachel Isaksson Vogel, Gregory J Metzger, Colleen L Forster, Lauren O Marston, Jessica R Tiffany, James B McCarthy, Eva A Turley, Christopher A Warlick, Jonathan C Henriksen, Stephen C Schmechel

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Prognostic multibiomarker signatures in prostate cancer (PCa) may improve patient management and provide a bridge for developing novel therapeutics and imaging methods. Our objective was to evaluate the association between expression of 33 candidate protein biomarkers and time to biochemical failure (BF) after prostatectomy.

Methods

PCa tissue microarrays were constructed representing 160 patients for whom clinicopathologic features and follow-up data after surgery were available. Immunohistochemistry for each of 33 proteins was quantified using automated digital pathology techniques. Relationships between clinicopathologic features, staining intensity, and time to BF were assessed. Predictive modeling using multiple imputed datasets was performed to identify the top biomarker candidates.

Results

In univariate analyses, lymph node positivity, surgical margin positivity, non-localized tumor, age at prostatectomy, and biomarkers CCND1, HMMR, IGF1, MKI67, SIAH2, and SMAD4 in malignant epithelium were significantly associated with time to BF. HMMR, IGF1, and SMAD4 remained significantly associated with BF after adjusting for clinicopathologic features while additional associations were observed for HOXC6 and MAP4K4 following adjustment. In multibiomarker predictive models, 3 proteins including HMMR, SIAH2, and SMAD4 were consistently represented among the top 2, 3, 4, and 5 most predictive biomarkers, and a signature comprised of these proteins best predicted BF at 3 and 5 years.

Conclusions

This study provides rationale for investigation of HMMR, HOXC6, IGF1, MAP4K4, SIAH2, and SMAD4 as biomarkers of PCa aggressiveness in larger cohorts.
Appendix
Available only for authorised users
Literature
1.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 2013, 63 (1): 11-30. 10.3322/caac.21166.CrossRefPubMed
2.
Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I: Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007, 177 (2): 540-545. 10.1016/j.juro.2006.10.097.CrossRefPubMed
3.
Frazier HA, Robertson JE, Humphrey PA, Paulson DF: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol. 1993, 149 (3): 516-518.PubMed
4.
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999, 281 (17): 1591-1597. 10.1001/jama.281.17.1591.CrossRefPubMed
5.
Han M, Partin AW, Pound CR, Epstein JI, Walsh PC: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin. 2001, 28 (3): 555-565. 10.1016/S0094-0143(05)70163-4.CrossRef
6.
Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R, Hofer MD, Febbo PG, Chinnaiyan AM, Rubin MA: Defining aggressive prostate cancer using a 12-gene model. Neoplasia. 2006, 8 (1): 59-68. 10.1593/neo.05664.CrossRefPubMedPubMedCentral
7.
Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, Scott KL, Signoretti S, Bardeesy N, Wang YA, Hill DE, Golub TR, Stampfer MJ, Wong WH, Loda M, Mucci L, Chin L, DePinho RA: SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011, 470 (7333): 269-273. 10.1038/nature09677.CrossRefPubMedPubMedCentral
8.
Ekici S, Cerwinka WH, Duncan R, Gomez P, Civantos F, Soloway MS, Lokeshwar VB: Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer. 2004, 112 (1): 121-129. 10.1002/ijc.20368.CrossRefPubMed
9.
Glinsky GV, Berezovska O, Glinskii AB: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005, 115 (6): 1503-1521. 10.1172/JCI23412.CrossRefPubMedPubMedCentral
10.
Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL: Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest. 2004, 113 (6): 913-923. 10.1172/JCI20032.CrossRefPubMedPubMedCentral
11.
12.
Korkes F, Castro MG, Zequi SD, Nardi L, Giglio LA, Peo AC: RHAMM immunohistochemical expression and androgen deprivation in normal peritumoural, hyperplasic and neoplastic prostate tissue. BJU international. 2013, doi:10.1111/bju.12339. [Epub ahead of print]
13.
Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A. 2004, 101 (3): 811-816. 10.1073/pnas.0304146101.CrossRefPubMedPubMedCentral
14.
Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R, Krajewski S, Mercola D, Carpenter PM, Bowtell D, Ronai ZA: Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer cell. 2010, 18 (1): 23-38. 10.1016/j.ccr.2010.05.024.CrossRefPubMedPubMedCentral
15.
Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D’Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR: Gene expression correlates of clinical prostate cancer behavior. Cancer cell. 2002, 1 (2): 203-209. 10.1016/S1535-6108(02)00030-2.CrossRefPubMed
16.
Stephenson AJ, Smith A, Kattan MW, Satagopan J, Reuter VE, Scardino PT, Gerald WL: Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer. 2005, 104 (2): 290-298. 10.1002/cncr.21157.CrossRefPubMedPubMedCentral
17.
18.
Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo JH: Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol. 2004, 22 (14): 2790-2799. 10.1200/JCO.2004.05.158.CrossRefPubMed
19.
Swanson GP, Basler JW: Prognostic factors for failure after prostatectomy. J Cancer Educ. 2010, 2: 1-19.
20.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005, 310 (5748): 644-648. 10.1126/science.1117679.CrossRefPubMed
21.
Shao L, Tekedereli I, Wang J, Yuca E, Tsang S, Sood A, Lopez-Berestein G, Ozpolat B, Ittmann M: Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res. 2012, 18 (24): 6648-6657. 10.1158/1078-0432.CCR-12-2715.CrossRefPubMedPubMedCentral
22.
Metzger GJ, Dankbar SC, Henriksen J, Rizzardi AE, Rosener NK, Schmechel SC: Development of multigene expression signature maps at the protein level from digitized immunohistochemistry slides. PloS One. 2012, 7 (3): e33520-10.1371/journal.pone.0033520.CrossRefPubMedPubMedCentral
23.
Sagnak L, Topaloglu H, Ozok U, Ersoy H: Prognostic significance of neuroendocrine differentiation in prostate adenocarcinoma. Clin Genitourin Cancer. 2011, 9 (2): 73-80. 10.1016/j.clgc.2011.07.003.CrossRefPubMed
24.
Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R: Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis. 2002, 5 (2): 123-127. 10.1038/sj.pcan.4500572.CrossRefPubMed
25.
Shurbaji MS, Kalbfleisch JH, Thurmond TS: Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol. 1995, 26 (1): 106-109. 10.1016/0046-8177(95)90122-1.CrossRefPubMed
26.
Nanda A, Chen MH, Renshaw AA, D’Amico AV: Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys. 2009, 74 (5): 1419-1423. 10.1016/j.ijrobp.2008.10.027.CrossRefPubMed
27.
Sabolch A, Feng FY, Daignault-Newton S, Halverson S, Blas K, Phelps L, Olson KB, Sandler HM, Hamstra DA: Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys. 2011, 81 (4): e351-e360. 10.1016/j.ijrobp.2011.01.063.CrossRefPubMed
28.
Rizzardi AE, Johnson AT, Vogel RI, Pambuccian SE, Henriksen J, Skubitz AP, Metzger GJ, Schmechel SC: Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol. 2012, 7: 42-10.1186/1746-1596-7-42.CrossRefPubMedPubMedCentral
29.
Krajewska M, Smith LH, Rong J, Huang X, Hyer ML, Zeps N, Iacopetta B, Linke SP, Olson AH, Reed JC, Krajewski S: Image analysis algorithms for immunohistochemical assessment of cell death events and fibrosis in tissue sections. J Histochem Cytochem. 2009, 57 (7): 649-663. 10.1369/jhc.2009.952812.CrossRefPubMedPubMedCentral
30.
Van Buuren S, Brand JPL, Groothuis-Oudshoorn CGM, Rubin DB: Fully conditional specification in multivariate imputation. J Stat Comput Sim. 2006, 76 (12): 1049-1064. 10.1080/10629360600810434.CrossRef
31.
van Buuren S, Groothuis-Oudshoorn K: Mice: multivariate Imputation by Chained Equations in R. J Stat Softw. 2011, 45 (3): 1-67.
32.
Simon N, Friedman J, Hastie T, Tibshirani R: Regularization Paths for Cox’s Proportional Hazards Model via Coordinate Descent. J Stat Softw. 2011, 39 (5): 1-13.CrossRefPubMedPubMedCentral
33.
Heagerty PJ, Lumley T, Pepe MS: Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000, 56 (2): 337-344. 10.1111/j.0006-341X.2000.00337.x.CrossRefPubMed
34.
Ali AM, Dawson SJ, Blows FM, Provenzano E, Ellis IO, Baglietto L, Huntsman D, Caldas C, Pharoah PD: Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer. Br J Cancer. 2011, 104 (4): 693-699. 10.1038/sj.bjc.6606078.CrossRefPubMedPubMedCentral
35.
Maxwell CA, McCarthy J, Turley E: Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions?. J Cell Sci. 2008, 121 (Pt 7): 925-932.CrossRefPubMed
36.
37.
Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, Moller P, Rinnab L, Rubin MA, Greiner J, Schmitt M, Kuefer R, Ringhoffer M: RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia. 2009, 11 (9): 956-963.CrossRefPubMedPubMedCentral
38.
Slevin M, Krupinski J, Gaffney J, Matou S, West D, Delisser H, Savani RC, Kumar S: Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol. 2007, 26 (1): 58-68. 10.1016/j.matbio.2006.08.261.CrossRefPubMed
39.
Nedvetzki S, Gonen E, Assayag N, Reich R, Williams RO, Thurmond RL, Huang JF, Neudecker BA, Wang FS, Turley EA, Naor D: RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci U S A. 2004, 101 (52): 18081-18086. 10.1073/pnas.0407378102.CrossRefPubMedPubMedCentral
40.
Tolg C, Hamilton SR, Zalinska E, McCulloch L, Amin R, Akentieva N, Winnik F, Savani R, Bagli DJ, Luyt LG, Cowman MK, McCarthy JB, Turley EA: A RHAMM mimetic peptide blocks hyaluronan signaling and reduces inflammation and fibrogenesis in excisional skin wounds. Am J Pathol. 2012, 181 (4): 1250-1270. 10.1016/j.ajpath.2012.06.036.CrossRefPubMedPubMedCentral
41.
Ramachandran S, Liu P, Young AN, Yin-Goen Q, Lim SD, Laycock N, Amin MB, Carney JK, Marshall FF, Petros JA, Moreno CS: Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene. 2005, 24 (1): 188-198. 10.1038/sj.onc.1207906.CrossRefPubMed
42.
McCabe CD, Spyropoulos DD, Martin D, Moreno CS: Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer. Cancer Res. 2008, 68 (6): 1988-1996. 10.1158/0008-5472.CAN-07-5843.CrossRefPubMedPubMedCentral
43.
Moon SM, Kim SA, Yoon JH, Ahn SG: HOXC6 is deregulated in human head and neck squamous cell carcinoma and modulates Bcl-2 expression. J Biol Chem. 2012, 287 (42): 35678-35688. 10.1074/jbc.M112.361675.CrossRefPubMedPubMedCentral
44.
Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, Schultz PG, Hampton GM: A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci U S A. 2006, 103 (10): 3775-3780. 10.1073/pnas.0600040103.CrossRefPubMedPubMedCentral
45.
Hao JM, Chen JZ, Sui HM, Si-Ma XQ, Li GQ, Liu C, Li JL, Ding YQ, Li JM: A five-gene signature as a potential predictor of metastasis and survival in colorectal cancer. J Pathol. 2010, 220 (4): 475-489.PubMed
46.
Liu AW, Cai J, Zhao XL, Jiang TH, He TF, Fu HQ, Zhu MH, Zhang SH: ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. Clin Cancer Res. 2011, 17 (4): 710-720. 10.1158/1078-0432.CCR-10-0331.CrossRefPubMed
47.
Qiu MH, Qian YM, Zhao XL, Wang SM, Feng XJ, Chen XF, Zhang SH: Expression and prognostic significance of MAP4K4 in lung adenocarcinoma. Pathol Res Pract. 2012, 208 (9): 541-548. 10.1016/j.prp.2012.06.001.CrossRefPubMed
48.
Massoner P, Ladurner Rennau M, Heidegger I, Kloss-Brandstatter A, Summerer M, Reichhart E, Schafer G, Klocker H: Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-beta treatment. Am J Pathol. 2011, 179 (6): 2905-2919. 10.1016/j.ajpath.2011.08.026.CrossRefPubMedPubMedCentral
49.
Montagnani Marelli M, Moretti RM, Procacci P, Motta M, Limonta P: Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the alphavbeta3 integrin and PI3-K/Akt signaling. Int J Oncol. 2006, 28 (3): 723-730.PubMed
50.
Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R, Burger R, Hideshima T, Chauhan D, Mitsiades N, Richardson P, Munshi NC, Kahn CR, Mitsiades C, Anderson KC: Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3’-kinase/AKT signaling. Cancer Res. 2003, 63 (18): 5850-5858.PubMed
51.
DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltran L, Moats S, Ramirez A, Jorcano J, Conti C: Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci U S A. 2000, 97 (7): 3455-3460. 10.1073/pnas.97.7.3455.CrossRefPubMedPubMedCentral
52.
Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schröder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, et al: Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med. 2008, 149 (7): 461-471. 10.7326/0003-4819-149-7-200810070-00006. W483-468CrossRefPubMedPubMedCentral
53.
Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, Troncoso P, Pettaway CA, Byun JY, Logothetis CJ: Prioritizing genes associated with prostate cancer development. BMC Cancer. 2010, 10: 599-CrossRefPubMedPubMedCentral
54.
MacGrogan D, Pegram M, Slamon D, Bookstein R: Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene. 1997, 15 (9): 1111-1114. 10.1038/sj.onc.1201232.CrossRefPubMed
55.
Elliott RL, Blobe GC: Role of transforming growth factor Beta in human cancer. J Clin Oncol. 2005, 23 (9): 2078-2093. 10.1200/JCO.2005.02.047.CrossRefPubMed
56.
Horvath LG, Henshall SM, Kench JG, Turner JJ, Golovsky D, Brenner PC, O’Neill GF, Kooner R, Stricker PD, Grygiel JJ, Sutherland RL: Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate. 2004, 59 (3): 234-242. 10.1002/pros.10361.CrossRefPubMed
57.
Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP, Ross JS: Smad4 protein expression correlates with grade, stage, and DNA ploidy in prostatic adenocarcinomas. Hum Pathol. 2005, 36 (11): 1204-1209. 10.1016/j.humpath.2005.08.015.CrossRefPubMed
58.
Piestrzeniewicz-Ulanska D, Brys M, Semczuk A, Rechberger T, Jakowicki JA, Krajewska WM: TGF-beta signaling is disrupted in endometrioid-type endometrial carcinomas. Gynecol Oncol. 2004, 95 (1): 173-180. 10.1016/j.ygyno.2004.06.032.CrossRefPubMed
59.
Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL, Massague J: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A. 2005, 102 (39): 13909-13914. 10.1073/pnas.0506517102.CrossRefPubMedPubMedCentral
60.
Nakayama K, Frew IJ, Hagensen M, Skals M, Habelhah H, Bhoumik A, Kadoya T, Erdjument-Bromage H, Tempst P, Frappell PB, Bowtell DD, Ronai Z: Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell. 2004, 117 (7): 941-952. 10.1016/j.cell.2004.06.001.CrossRefPubMed
61.
Qi J, Tripathi M, Mishra R, Sahgal N, Fazli L, Ettinger S, Placzek WJ, Claps G, Chung LW, Bowtell D, Gleave M, Bhowmick N, Ronai ZA: The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer cell. 2013, 23 (3): 332-346. 10.1016/j.ccr.2013.02.016.CrossRefPubMedPubMedCentral
62.
Koopmeiners JS, Vogel RI: Early termination of a two-stage study to develop and validate a panel of biomarkers. Stat Med. 2013, 32 (6): 1027-1037. 10.1002/sim.5622.CrossRefPubMed
Metadata
Title
Evaluation of protein biomarkers of prostate cancer aggressiveness
Authors
Anthony E Rizzardi
Nikolaus K Rosener
Joseph S Koopmeiners
Rachel Isaksson Vogel
Gregory J Metzger
Colleen L Forster
Lauren O Marston
Jessica R Tiffany
James B McCarthy
Eva A Turley
Christopher A Warlick
Jonathan C Henriksen
Stephen C Schmechel
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-244

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response

Research article

GLUT-1 expression is largely unrelated to both hypoxia and the Warburg phenotype in squamous cell carcinomas of the vulva

Research article

Detection of infectious organisms in archival prostate cancer tissues

Research article

N-nitroso-N-ethylurea activates DNA damage surveillance pathways and induces transformation in mammalian cells

Research article

Concerted down-regulation of immune-system related genes predicts metastasis in colorectal carcinoma

Research article

RETRACTED ARTICLE: Identification of novel signaling components in N,N’-Dinitrosopiperazine-mediated metastasis of nasopharyngeal Carcinoma by quantitative phosphoproteomics
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits